Skip to NavigationSkip to content

AbbVie expands oncology portfolio with $5.8 billion Stemcentrx acquisition

Published on 29/04/16 at 08:24am

AbbVie (NYSE: ABBV) has announced the acquisition of Stemcentrx, and its lead late stage, lung cancer candidate Rova-T (rovalpituzumab tesirine), in a deal worth $5.8 billion.

Under the terms of the deal, AbbVie will pay approximately $2 billion in cash and fund the remaining portion with stock. The company expect the transaction to decrease earnings per share by $0.20, with accretion beginning in 2020.

Stemcentrx has four compounds in clinical trials across several solid tumour indications and Rova-T is one that has been submitted to the US FDA for breakthrough therapy designation. It is a biomarker-specific therapy that is derived from cancer stem cells and targets delta-like protein 3 (DLL3) that is expressed in more than 80% of small cell lung cancer patient tumours. As a targeted antibody, it deliversa cytotoxic agent directly to the DLL3-expressing cancer cells while minimising toxicity to healthy cells.

In Phase I/II studies, Rova-T demonstrated overall response rates of 44% in patients with a high expression of DLL3. This efficacy suggests the compound may also beneficial in treating other forms of cancer which express DLL3, such as metastatic melanoma, prostate, pancreatic and colorectal cancers.

Richard A. Gonzalez, chairman and CEO at AbbVie, says: “The addition of Stemcentrx and its late-stage compound Rova-T provide AbbVie with a unique platform in solid tumour therapeutics and complement our leadership position in haematologic oncology. We believe the acquisition of Stemcentrx will strengthen and accelerate our ability to deliver innovative therapies that will have a remarkable impact on patient lives.”

AbbVie currently markets Imbruvica and Venclexta, which treat chronic lymphocytic leukaemia.

Sean Murray

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches